Tumour-associated macrophage-derived interleukin-1 mediates glioblastoma-associated cerebral oedema

Abstract

Dexamethasone is used to manage cerebral oedema in patients with glioblastoma, despite significant drawbacks. Herting et al. show that dexamethasone reduces oedema via inhibition of interleukin-1 signalling. They highlight a likely interaction between dexamethasone and immunotherapy, and propose that specific interleukin-1 inhibition may be preferable to dexamethasone for managing oedema.